160 related articles for article (PubMed ID: 15138609)
21. Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein.
Kamikubo Y; Neels JG; Degryse B
Int J Biochem Cell Biol; 2009 Mar; 41(3):578-85. PubMed ID: 18703159
[TBL] [Abstract][Full Text] [Related]
22. The plasminogen activator inhibitor "paradox" in cancer.
Binder BR; Mihaly J
Immunol Lett; 2008 Jun; 118(2):116-24. PubMed ID: 18495253
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
24. The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as PAI-1 inhibitors.
Gils A
Verh K Acad Geneeskd Belg; 2006; 68(3):179-98. PubMed ID: 16796017
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
[TBL] [Abstract][Full Text] [Related]
27. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
28. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
30. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin.
Declerck PJ; Gils A
Semin Thromb Hemost; 2013 Jun; 39(4):356-64. PubMed ID: 23504606
[TBL] [Abstract][Full Text] [Related]
31. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
Samarakoon R; Higgins CE; Higgins SP; Kutz SM; Higgins PJ
J Cell Physiol; 2005 Jul; 204(1):236-46. PubMed ID: 15622520
[TBL] [Abstract][Full Text] [Related]
32. Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Rømer MU; Kirkebjerg Due A; Knud Larsen J; Hofland KF; Christensen IJ; Buhl-Jensen P; Almholt K; Lerberg Nielsen O; Brünner N; Lademann U
Thromb Haemost; 2005 Oct; 94(4):859-66. PubMed ID: 16270643
[TBL] [Abstract][Full Text] [Related]
33. Membrane-type 1 matrix metalloproteinase modulates focal adhesion stability and cell migration.
Takino T; Watanabe Y; Matsui M; Miyamori H; Kudo T; Seiki M; Sato H
Exp Cell Res; 2006 May; 312(8):1381-9. PubMed ID: 16473349
[TBL] [Abstract][Full Text] [Related]
34. [Regulation of PAI-1 expression].
Wyrzykowska P; Kasza A
Postepy Biochem; 2009; 55(1):46-53. PubMed ID: 19514465
[TBL] [Abstract][Full Text] [Related]
35. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
36. Involvement of plasminogen activator and plasminogen activator inhibitor type 1 in spermatogenesis, sperm capacitation, and fertilization.
Liu YX
Semin Thromb Hemost; 2007 Feb; 33(1):29-40. PubMed ID: 17253187
[TBL] [Abstract][Full Text] [Related]
37. [The influence of nitric oxide on the regulation of plasminogen activator inhibitor type 1 and tissue-type plasminogen activator expression].
Oszajca K; Szemraj J; Bartkowiak J
Postepy Biochem; 2005; 51(4):407-13. PubMed ID: 16676575
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
39. The ternary complex factor Net regulates cell migration through inhibition of PAI-1 expression.
Buchwalter G; Gross C; Wasylyk B
Mol Cell Biol; 2005 Dec; 25(24):10853-62. PubMed ID: 16314510
[TBL] [Abstract][Full Text] [Related]
40. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury.
Fay WP
Trends Cardiovasc Med; 2004 Jul; 14(5):196-202. PubMed ID: 15261892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
